ArticleNature communications2024
Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
20.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Pooled it
- A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID.Nature communications · 2025Pooled it
- A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.Scientific reports · 2024Pooled it
- Long COVID is associated with lipoxygenase-catalyzed metabolism of essential polyunsaturated fatty acids.iScience · 2026Article
- Virus reactivation in acute and long COVID-19.Nature · 2026Article
- Long COVID longitudinal symptoms burden clusters within a national community-based cohort.BMC infectious diseases · 2026Article
- Exploration of immune phenotypes in self-sampling citizens.iScience · 2026Article
- Extensive Immunological and Inflammatory Perturbation Underpins the Respiratory Sequelae of Postacute COVID-19.Open forum infectious diseases · 2026Article
- Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors.Communications medicine · 2026Article
- Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort.PloS one · 2026Article
- Identifying subtypes of Long COVID: a systematic review.EClinicalMedicine · 2026Article
- Persistent neurological and behavioral alterations after SARS-CoV-2 infection in an optimized K18-hACE2 mouse model.Frontiers in microbiology · 2026Article
- Symptoms, mechanisms, and management of long COVID: understanding its prevalence, characteristics, and healthcare challenges in Saudi Arabia.Frontiers in cellular and infection microbiology · 2026Review
- MTHFR allele and one-carbon metabolic profile predict severity of COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Long COVID Longitudinal Symptoms Burden Clusters Within A National Community-Based Cohort.medRxiv : the preprint server for health sciences · 2025Article
- A multiomics recovery factor predicts long COVID in the IMPACC study.The Journal of clinical investigation · 2025Article
- Long COVID: current research and future directions.Infectious diseases & immunity · 2025Review
- Objective and Subjective Voice Outcomes in Post-COVID-19 Dysphonia: A High-Speed Videoendoscopy Pre-Post Study.Journal of clinical medicine · 2025Article
- Acute serum protein biomarker profile and prevalence of persistent (>6 months) neuropsychiatric symptoms in a cohort of SARS-CoV-2 PCR positive patients in Cape Town, South Africa.Brain, behavior, & immunity - health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
58 authors at 20 institutions in 2 countries.
Al Ozonoff *Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0003-4233-5899
Naresh Doni Jayavelu *Benaroya Research Institute, Seattle, WA, USA.
Shanshan Liu *Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Esther Melamed *The University of Texas at Austin, Austin, TX, USA.
Carly E Milliren *Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Jingjing Qi *Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Linda N Geng *Stanford University, Stanford, CA, USA.
Grace A McComseyCase Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA.
Charles B CairnsDrexel University/Tower Health Hospital, Philadelphia, PA, USA.ORCID 0000-0003-2291-5415
Lindsey R BadenBoston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Joanna SchaenmanDavid Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Albert C ShawYale School of Medicine, and Yale School of Public Health, New Haven, CT, USA.
Hady SamahaEmory University, Atlanta, GA, USA.ORCID 0000-0002-9124-7820
Vicki Seyfert-MargolisMyOwnMed, Inc, Bethesda, MD, USA.
Florian KrammerIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-4121-776X
Lindsey B RosenNational Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.
Hanno SteenBoston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0179-6648
Caitlin SyphursClinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Ravi DandekarUniversity of California San Francisco School of Medicine, San Francisco, CA, USA.
Casey P ShannonCentre for Heart Lung Innovation, Providence Research, St. Paul's Hospital, and the PROOF Centre of Excellence, Vancouver, BC, Canada.ORCID 0000-0002-5687-3156
Rafick P SekalyCase Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA.ORCID 0000-0002-7816-4828
Lauren I R EhrlichThe University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-1697-1755
David B CorryBaylor College of Medicine, and the Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, Houston, TX, USA.
Farrah KheradmandBaylor College of Medicine, and the Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, Houston, TX, USA.ORCID 0000-0001-5343-103X
Mark A AtkinsonUniversity of Florida/University of South Florida, Tampa, FL, USA.
Scott C BrakenridgeUniversity of Florida/University of South Florida, Tampa, FL, USA.
Nelson I Agudelo HiguitaOklahoma University Health Sciences Center, Oklahoma City, OK, USA.
Jordan P MetcalfOklahoma University Health Sciences Center, Oklahoma City, OK, USA.
Catherine L HoughOregon Health & Science University, Portland, OR, USA.
William B MesserOregon Health & Science University, Portland, OR, USA.ORCID 0000-0002-4381-6347
Bali PulendranStanford University, Stanford, CA, USA.ORCID 0000-0001-6517-4333
Kari C NadeauStanford University, Stanford, CA, USA.ORCID 0000-0002-2146-2955
Mark M DavisStanford University, Stanford, CA, USA.ORCID 0000-0001-6868-657X
Ana Fernandez SesmaIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3405-6702
Viviana SimonIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6416-5096
Harm van BakelIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-1376-6916
Seunghee Kim-SchulzeIcahn School of Medicine at Mount Sinai, New York, NY, USA.
David A HaflerYale School of Medicine, and Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0003-4664-535X
Ofer LevyBoston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5859-1945
Monica KraftUniversity of Arizona, Tucson, AZ, USA.
Chris BimeUniversity of Arizona, Tucson, AZ, USA.
Elias K HaddadDrexel University/Tower Health Hospital, Philadelphia, PA, USA.ORCID 0000-0001-6924-4300
Carolyn S CalfeeUniversity of California San Francisco School of Medicine, San Francisco, CA, USA.
David J ErleUniversity of California San Francisco School of Medicine, San Francisco, CA, USA.ORCID 0000-0002-2171-0648
Charles R LangelierUniversity of California San Francisco School of Medicine, San Francisco, CA, USA.ORCID 0000-0002-6708-4646
Walter EckalbarUniversity of California San Francisco School of Medicine, San Francisco, CA, USA.
Steven E BosingerEmory University, Atlanta, GA, USA.ORCID 0000-0002-2116-5061
IMPACC Network
Bjoern PetersLa Jolla Institute for Immunology, La Jolla, CA, USA.ORCID 0000-0002-8457-6693
Steven H KleinsteinYale School of Medicine, and Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0003-4957-1544
Elaine F ReedDavid Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Alison D AugustineNational Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.
Joann Diray-ArceClinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Holden T MaeckerStanford University, Stanford, CA, USA.ORCID 0000-0003-0795-9946
Matthew C AltmanBenaroya Research Institute, Seattle, WA, USA.ORCID 0000-0002-1784-8505
Ruth R MontgomeryYale School of Medicine, and Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0002-8661-4454
Patrice M BeckerNational Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-1170-8587
Nadine RouphaelEmory University, Atlanta, GA, USA. nroupha@emory.edu.ORCID 0000-0002-2512-7919
University of California, San Francisco · USBrigham and Women's Hospital · USEmory University · USIcahn School of Medicine at Mount Sinai · USYale University · USDrexel University · USBoston Children's Hospital · USStanford University · USUniversity of Arizona · USUniversity of California, Los Angeles · USUniversity Hospitals of Cleveland · USNational Institutes of Health · USOregon Health & Science University · USThe University of Texas at Austin · USUniversity of South Florida · USLa Jolla Institute for Immunology · USMichael E. DeBakey VA Medical Center · USBenaroya Research InstituteOU HealthSt. Paul's Hospital · CA
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUsing a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MTranslation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2004 to 2023
$56.2MSystems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI David A. Hafler, RUTH R MONTGOMERY · 2010 to 2026
$50.4MProject 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KASARSKIS, ANDREW · 2015 to 2021
$46.6MSystems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0MUnderstanding Asthma EndotypesU19AI077439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David J Erle · 2008 to 2026
$41.1MClinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1MTranscriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OZONOFF, AL · 2017 to 2021
$24.7MThe effects of immune-age on immune-response and the molecular mechanisms which drive itP01AI153559 · NIAID · STANFORD UNIVERSITY · PI SHEN-ORR, SHAI SHLOMO · 2021 to 2025
$17.8MTollip inhibits IL-33 signaling during airway influenza virus infectionU19AI125357 · NIAID · UNIVERSITY OF ARIZONA · PI KRAFT, MONICA · 2016 to 2025
$14.7MSystems Immunology profiling of respiratory viral infections in vulnerable populationsU19AI167891 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Matthew C. Altman, Carmen R Mikacenic · 2022 to 2026
$14.0MNCATS NIH HHS UL1 TR001863NCATS NIH HHS UM1 TR004528NHLBI NIH HHS U01 HL163124NIAID NIH HHS P01 AI153559NIAID NIH HHS R01 AI104870NIAID NIH HHS R01 AI132774NIAID NIH HHS R01 AI135201NIAID NIH HHS R01 AI135803NIAID NIH HHS R01 AI145835NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI062629NIAID NIH HHS U19 AI077439NIAID NIH HHS U19 AI089992NIAID NIH HHS U19 AI090023NIAID NIH HHS U19 AI118608NIAID NIH HHS U19 AI118610NIAID NIH HHS U19 AI125357NIAID NIH HHS U19 AI128910NIAID NIH HHS U19 AI128913NIAID NIH HHS U19 AI167903NIAID NIH HHS U54 AI142766NIH HHS S10 OD026880NIH HHS S10 OD030363NIH HHS S10 OD030463
Abstract
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities. During the acute phase of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike antibody titers were associated with both the physical predominant and the multidomain deficit clusters. A lower frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain deficit cluster. Circulating fibroblast growth factor 21 (FGF21) was significantly elevated in the mental/cognitive predominant and the multidomain clusters. Future efforts to link PASC to acute anti-viral host responses may help to better target treatment and prevention of PASC.
Indexed as
Body FluidsCOVID-19B-LymphocytesDisease ProgressionFemaleHumansPhenotypeSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.